Congestive Heart Failure: Major World Markets, Volume II: Devices (Pacemaker, ICD, LVAD and Artificial Heart Markets)

Table of Contents

• Background
• Scope and Methodology
• Size and Growth of Market

• Backgroun
• Pathophysiolog
• Types of Heart Failur
• Left Ventricular (LV) Failure
• Right Ventricular (RV) Failure
• Systolic Dysfunction
• Diastolic Dysfunction
• High Output Failure
• Theories of Congestive Heart Failure
• Hemodynamic Response Theory
• Neurohormonal Response Theory
• Renal Response Theory
• Conditions Leading to Congestive Heart Failure
• Myocardial Infarction
• Hypertension
• Cardiomyopathy
• Atrial Fibrillation
• Other Risk Factor
• Diagnosis of Congestive Heart Failure
• Classification of Congestive Heart Failure Patients
• Epidemiolog
• United States
• Europe
• Japan

• Artificial Pacemaker
• Ventricular Assist Devices (VADs)
• Total Artificial Hearts (TAHs)
• American College of Cardiology Guideline

• Guidelines for Management of Chronic Heart Failur
• Strategies to Maintain Quality Patient Care and Contain Costs

• United States
• Europe
• Japan

• Abbott Laboratories
• Abiomed, Inc.
• Ambu, USA
• Aortech International, plc
• Arrow International
• Atrium Medical Corporation
• ATS Medical, Inc.
• Bacchus Vascular, Inc.
• Berlin Heart AG
• Biophan Technologies, Inc.
• Biosensors International
• Biotronik, Inc.
• Boston Scientific
• CardiacAssist, Inc.
• Cardiac Science Corporation
• Cardiogenesis Corporation
• Cordis Corporation/Biologics Delivery Systems
• CoreValve, Inc.
• CryoCath Technologies, Inc.
• Cryocor, Inc.
• Datascope
• Defibtech, LLC
• Deltex Medical
• Heartlab
• Impulse Dynamics USA, Inc.
• MedicalCV, Inc.
• Medtronic, Inc.
• Orqis Medical Corporation
• Sorin SpA
• Stereotaxis, Inc.
• St. Jude Medical, Inc.
• Teleflex Medical
• Terumo Heart, Inc.
• Thoratec Corporation
• Ventracor, Inc.
• Volcano Corporation

• First Conclusion
• Second Conclusion
• Implications:
• Third Conclusion
• Implications:
• Fourth Conclusion
• Implications:
• Fifth Conclusion
• Implications:
• Sixth Conclusion
• Implications:
• Seventh Conclusion
• Implications:
• Eighth Conclusion
• Implications:
• APPENDIX A

• Figure 1-1: Incidence of Congestive Heart Failure Cases in the Major World Healthcare Markets: 2007 - 2017
• Figure 1-2: Prevalence of Congestive Heart Failure Cases in the Major World -Healthcare Markets: 2007 - 2017
• Table 1-1: The Estimated Markets for Devices Used to Treat CHF in the Major World Healthcare Markets by Geographic Segment
• Figure 1-3 1Trending in the Estimated Markets for Devices Used to Treat CHF in the Major World Healthcare Markets by Geographic Segment..
• Figure 1-4: Distribution of the Estimated Markets for Devices Used to Treat CHF in the Major World Healthcare Markets by Geographic Segment

• Table 2-1: International Cardiovascular Disease (CVD) Statistics -
• Table 2-2: United States CHF Statistics: 2004
• Table 2-3: CHF Data Sources
• Table 2-4: Common Contributors to Congestive Heart Failure
• Figure 2-1: Incidence and Prevalence of Congestive Heart Failure In the World' s Major Healthcare Markets: 2007 - 2017
• Figure 2-2: Incidence Rates of Congestive Heart Failure in the Major World Healthcare Markets: 200l - 2017 (Cases per Million Population)
• Figure 2-3: Prevalence Rates of Congestive Heart Failure in the Major World Healthcare Markets: 2007 - 2017 (Cases per Million Population)
• Figure 2-4: Percentage Breakdown of Deaths from Cardiovascular Diseases: 2003 -
• Table 2-5: Incidence and Prevalence of CHF in the United States:-- 2007 - 2017- -
• Figure 2-5: Incidence and Prevalence of CHF in the United States:-- 2007 - 20017- -
• Figure 2-6: The Distribution of Congestive Heart Failure In the Five Major European Healthcare Markets:- 2007
• Table 2-6: Incidence and Prevalence of CHF in the Major Healthcare Markets of Europe:- 2007 - 2017- (Thousands)
• Figure 2-7: Incidence and Prevalence of CHF in the Major Healthcare Markets of Europe:- 2007 - 20017 (Thousands) -
• Table 2-7: Incidence and Prevalence of CHF in Japan:- 2007 - 2017
• Figure 2-8: Incidence and Prevalence of CHF in Japan:- 2007 - 20017

• Table 3-1: Key Implantable Heart Pacing Devices
• Table 3-2: Vascular Assist Devices
• Table 3-3: Total Artificial Heart Devices
• Table 3-4: Facilities Authorized to Performs Total Artificial Heart Implants

• Figure 4-1: ACC/AHA Guideline Summary for Recommended Therapy of -Congestive Heart Failure by Stage of the Disease
• Table 4-1: ACC/AHA Staging of Congestive Heart Failure
• Table 4-2: 2005 ACC/AHA Guidelines for Evaluation and Therapy for Congestive Heart Failure:

• Table 5-1: The Estimated Markets for Devices Used to Treat CHF in the Major World Healthcare Markets by Geographic Segment -
• Figure 5-1: Trending in the Estimated Markets for Devices Used to Treat CHF in the Major World Healthcare Markets by Geographic Segment
• Figure 5-2: Distribution of the Estimated Markets for Devices Used- to Treat CHF in the Major World Healthcare Markets- by Geographic Segment
• Table 5-2: The Estimated Markets for Devices Used to Treat CHF in the Major World Healthcare Markets by Device Segment-
• Figure 5-3: Trending in the Estimated Markets for Devices to Treat CHF in the Major World Healthcare Markets by Device Segment
• Figure 5-4: Distribution of the Estimated Markets for Devices to Treat CHF in the Major World Healthcare Markets by Device Segment
• Table 5-3: The Estimated Markets for Devices Used to Treat CHF in the United States Healthcare Market by Device Segment (Pacemakers, ICDs, LVADs, and TAHs) -
• Figure 5-5: Trending in the Estimated Markets for Devices Used to Treat CHF -in the United States Healthcare Market by Device Segment
• Figure 5-6: Distribution of the Estimated Markets for Devices Used to Treat CHF in the United States Healthcare Market by Device Segment
• Table 5-4: The Estimated Markets for Devices Used to Treat CHF in the -Five Major European Healthcare Markets by Device Segment-
• Figure 5-7: Trending the Estimated Markets for Devices Used to Treat- CHF in the Five Major European Healthcare Markets by- Device Segment
• Figure 5-8: Distribution of the Estimated Markets for Devices Used to Treat CHF in the Five Major European Healthcare Markets by Device Segment
• Table 5-5: The Estimated Markets for Devices Used to Treat CHF in the Japanese Healthcare Market by Device Segment-
• Figure 5-9: Trending in the Estimated Markets for Devices Used to Treat CHF in the Japanese Healthcare Market by Device Segment
• Figure 5-10: Distribution of the Estimated Markets for Devices Used to Treat CHF in the Japanese Healthcare Market by Device Segment